Cargando…
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐line chemotherapy regimens
BACKGROUND: Front‐line platinum‐base chemotherapy for advanced thymoma and thymic carcinoma (TC) improves resectability and prolongs patients' overall survival (OS). In this study, we evaluated patients' outcomes given different front‐line regimens: cisplatin, doxorubicin, and cyclophospha...
Autores principales: | Ma, Wei‐Li, Lin, Chia‐Chi, Hsu, Feng‐Ming, Lee, Jang‐Ming, Chen, Jin‐Shing, Huang, Yen‐Lin, Chang, Yih‐Leong, Chang, Chin‐Hao, Yang, James Chih‐Hsin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487882/ https://www.ncbi.nlm.nih.gov/pubmed/35348307 http://dx.doi.org/10.1002/cam4.4711 |
Ejemplares similares
-
Long term oncological outcome of thymoma and thymic carcinoma – an analysis of 235 cases from a single institution
por: Tseng, Yen-Chiang, et al.
Publicado: (2017) -
Correction: Long term oncological outcome of thymoma and thymic carcinoma - an analysis of 235 cases from a single institution
por: Tseng, Yen-Chiang, et al.
Publicado: (2017) -
Thymic carcinoid tumor combined with thymoma--neuroendocrine differentiation in thymoma?
por: Cho, K. J., et al.
Publicado: (1993) -
Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States
por: Hsu, Chun-Hsiang, et al.
Publicado: (2019) -
Viral infection in thymoma and thymic tumors with autoimmune diseases
por: Chang, Rui, et al.
Publicado: (2021)